JSB Market Research: Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90–95% of all melanomas. See Full Report @ bit.ly/1sthPU6
Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90–95% of all melanomas.
See Full Report @ bit.ly/1sthPU6
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong> <strong>to</strong> <strong>2020</strong> - <strong>Rising</strong><br />
<strong>Prevalence</strong> <strong>and</strong> <strong>Evolving</strong> <strong>Treatment</strong> <strong>Algorithms</strong> <strong>to</strong> <strong>Drive</strong><br />
<strong>Market</strong> <strong>Growth</strong><br />
On 16 th December 2014<br />
Summary<br />
A leading business intelligence provider, has released its latest research report, "<strong>Melanoma</strong><br />
<strong>Therapeutics</strong> <strong>Market</strong> <strong>to</strong> <strong>2020</strong> - <strong>Rising</strong> <strong>Prevalence</strong> <strong>and</strong> <strong>Evolving</strong> <strong>Treatment</strong> <strong>Algorithms</strong> <strong>to</strong> <strong>Drive</strong><br />
<strong>Market</strong> <strong>Growth</strong>”<br />
<strong>Melanoma</strong> is a highly heterogeneous disease comprising Cutaneous <strong>Melanoma</strong> (CM), Ocular<br />
<strong>Melanoma</strong> (OM), Mucosal <strong>Melanoma</strong> (MM), melanoma of the internal organs, <strong>and</strong>, according<br />
<strong>to</strong> some classifications, melanoma of the soft parts (non-bony <strong>and</strong> non-cartilaginous tissues) of<br />
the body. CM is by far the most common form of melanoma, accounting for approximately 90–<br />
95% of all melanomas.<br />
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-melanoma-therapeutics-market-<strong>to</strong>-<strong>2020</strong>-rising-prevalence-<strong>and</strong>evolving-treatment-algorithms-<strong>to</strong>-drive-market-growth-138194<br />
His<strong>to</strong>rically, melanoma has been considered as a very challenging disease <strong>to</strong> treat with<br />
pharmacotherapy. However, in recent years, underst<strong>and</strong>ing of the pathophysiology <strong>and</strong><br />
heterogeneity of melanoma, <strong>and</strong> particularly CM, has developed considerably. This has led <strong>to</strong><br />
the approval of several new drug agents indicated for CM since 2011, namely Sylatron<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
(peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab),<br />
Zelboraf (vemurafenib), Tafinlar (dabrafenib) <strong>and</strong> Mekinist (trametinib). These drugs have<br />
dramatically improved the treatment options for CM patients, leading <strong>to</strong> unprecedented<br />
market growth.<br />
Rapid market growth is also anticipated over the forecast period due <strong>to</strong> the exp<strong>and</strong>ing<br />
melanoma treatment population <strong>and</strong> the continued uptake of recently approved drugs. The<br />
melanoma pipeline is currently strong, with several promising molecules in development<br />
including, Polynoma’s seviprotimut-L, Amgen’s talimogene laherparepvec (T-VEC) <strong>and</strong> Roche<br />
<strong>and</strong> Genentech’s cobimetinib in combination with Zelboraf, which are in development for CM,<br />
as well as AstraZeneca’s selumetinib which is in development for OM. Consequently, the<br />
melanoma therapeutics market is projected <strong>to</strong> grow from $1.3 billion in 2013 <strong>to</strong> $3.6 billion in<br />
<strong>2020</strong>, at a CAGR of 15.4%.<br />
Scope<br />
The report analyzes treatment usage patterns, drug types available <strong>and</strong> pipeline <strong>and</strong> market<br />
forecasts across indications for melanoma.The report covers <strong>and</strong> includes -<br />
- An introduction <strong>to</strong> the melanoma indication, including disease symp<strong>to</strong>ms, epidemiology,<br />
etiology, pathophysiology, staging, diagnosis <strong>and</strong> treatment.<br />
- In-depth analysis of the current melanoma marketed products l<strong>and</strong>scape including product<br />
profiles of the main drugs used in melanoma <strong>and</strong> heat maps that compare safety <strong>and</strong> efficacy<br />
parameters of the various drugs.<br />
- Comprehensive analysis of the melanoma pipeline by phase of development, molecule type,<br />
molecular target <strong>and</strong> novelty. A comparative analysis of late-stage pipeline drugs that are likely<br />
<strong>to</strong> enter the market in the forecast period is also provided alongside heat maps.<br />
- Additional in-depth analysis of melanoma clinical trials by size, duration, failure rates <strong>and</strong><br />
primary <strong>and</strong> secondary endpoints.<br />
- Multi-scenario forecast data for the market <strong>to</strong> <strong>2020</strong>, taking in<strong>to</strong> account how it will be<br />
affected by the introduction of new drugs <strong>and</strong> changes in disease epidemiology across the key<br />
developed markets, the US, Canada, the UK, France, Germany, Italy, Spain <strong>and</strong> Japan.<br />
- Discussion of the licensing <strong>and</strong> co-development strategic consolidations l<strong>and</strong>scape in<br />
melanoma, by Phase of development <strong>and</strong> molecule type, as well as an analysis of both licensing<br />
<strong>and</strong> co-development deals by year, <strong>and</strong> network maps of licensing <strong>and</strong> co-development deals.<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Reasons <strong>to</strong> buy<br />
The report will assist business development <strong>and</strong> enable marketing executives <strong>to</strong> strategize their<br />
product launches, by allowing them <strong>to</strong><br />
- Gain a comprehensive underst<strong>and</strong>ing of the melanoma indication including segmentation of<br />
disease <strong>and</strong> treatment algorithms.<br />
- Underst<strong>and</strong> the current melanoma marketed products l<strong>and</strong>scape <strong>and</strong> recognize the dominant<br />
therapeutic agents <strong>and</strong> pharmaceutical players involved.<br />
- Identify trends <strong>and</strong> developments within the melanoma pipeline including which molecule<br />
types <strong>and</strong> molecular targets are prominent.<br />
- Consider market opportunities <strong>and</strong> potential risks by examining trends in melanoma clinical<br />
trial duration <strong>and</strong> size, as well as clinical trial failure rates, amongst clinical trial Phases <strong>and</strong><br />
molecule types.<br />
- Assess the potential clinical <strong>and</strong> commercial impact of current late-stage pipeline molecules<br />
on the melanoma therapeutics market.<br />
Other industries we cover:<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Advertising <strong>and</strong> Media<br />
Au<strong>to</strong>motive <strong>and</strong> Parts<br />
Consumer Goods<br />
Healthcare <strong>and</strong> Medical<br />
Finance <strong>and</strong> Banking<br />
Food <strong>and</strong> Beverages<br />
Travel <strong>and</strong> Tourism<br />
Textiles <strong>and</strong> Clothing<br />
SWOT Analysis<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Discounts on <strong>Market</strong> <strong>Research</strong> Reports till 31st December, 2014<br />
For more inquiries, contact at +91 - 998 729 5242 /<br />
contact@jsbmarketresearch.com<br />
Table of Content<br />
1.1 List of Tables 8<br />
1.2 List of Figures 9<br />
2 Introduction 11<br />
2.1 Disease Introduction 11<br />
2.2 Types of <strong>Melanoma</strong> 12<br />
2.3 Symp<strong>to</strong>ms 13<br />
2.3.1 Cutaneous <strong>Melanoma</strong> 13<br />
2.3.2 Ocular <strong>Melanoma</strong> 14<br />
2.3.3 Mucosal <strong>Melanoma</strong>s 14<br />
2.3.4 <strong>Melanoma</strong>s of the Internal Organs <strong>and</strong> Soft Parts 14<br />
2.3.5 Advanced <strong>Melanoma</strong> 15<br />
2.4 Etiology <strong>and</strong> Risk Fac<strong>to</strong>rs 15<br />
2.4.1 Phenotypic Characteristics 15<br />
2.4.2 Exposure <strong>to</strong> Ultraviolet Radiation 16<br />
2.4.3 Personal or Family His<strong>to</strong>ry of <strong>Melanoma</strong> 17<br />
2.4.4 Xeroderma Pigmen<strong>to</strong>sum 18<br />
2.4.5 Parkinson’s Disease 18<br />
2.5 Pathophysiology 18<br />
2.5.1 Cutaneous <strong>Melanoma</strong> 18<br />
2.5.2 Ocular <strong>Melanoma</strong> 19<br />
2.5.3 Mucosal <strong>Melanoma</strong> 20<br />
2.5.4 Underlying Molecular Pathways 20<br />
2.6 <strong>Melanoma</strong> Staging 22<br />
2.7 Diagnosis 25<br />
2.7.1 Cutaneous <strong>Melanoma</strong> 25<br />
2.7.2 Ocular <strong>Melanoma</strong> 25<br />
2.7.3 Mucosal <strong>Melanoma</strong> 26<br />
2.8 Epidemiology 26<br />
2.8.1 Cutaneous <strong>Melanoma</strong> 26<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
2.8.2 Ocular <strong>Melanoma</strong> 27<br />
2.8.3 Mucosal <strong>Melanoma</strong> 28<br />
2.9 <strong>Treatment</strong> Options 28<br />
2.9.1 Surgery 29<br />
2.9.2 Radiation Therapy 29<br />
2.9.3 Pharmacotherapy 30<br />
2.10 <strong>Treatment</strong> <strong>Algorithms</strong> 31<br />
2.10.1 Cutaneous <strong>Melanoma</strong> 31<br />
2.10.2 Ocular <strong>Melanoma</strong> 32<br />
2.10.3 Mucosal <strong>Melanoma</strong> 33<br />
2.11 <strong>Treatment</strong> Segments 34<br />
2.11.1 Adjuvant Therapy for CM (All Mutations) 35<br />
2.11.2 Advanced Therapy for CM (All Mutations) 37<br />
2.11.3 Advanced Therapy for CM (BRAF Mutated Patients Only) 44<br />
3 <strong>Market</strong>ed Products 49<br />
3.1 Overview 49<br />
3.2 Adjuvant therapy 50<br />
3.2.1 Immunotherapy 50<br />
3.3 Therapy for Advanced (Unresectable or Metastatic) <strong>Melanoma</strong> 52<br />
3.3.1 Chemotherapy 52<br />
3.3.2 Immunotherapy 54<br />
3.3.3 Targeted Therapies 59<br />
3.4 Heat Maps for <strong>Market</strong>ed Products 62<br />
4 <strong>Melanoma</strong> Pipeline 68<br />
4.1 Overview 68<br />
4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration <strong>and</strong><br />
Novelty 70<br />
4.3 Pipeline Distribution by Molecular Target 76<br />
4.4 Clinical Trial L<strong>and</strong>scape 82<br />
4.4.1 Clinical Trial Failure Rates 82<br />
4.4.2 Clinical Trial Duration 86<br />
4.4.3 Clinical Trial Size 89<br />
4.4.4 Primary <strong>and</strong> Secondary Endpoints 91<br />
4.5 Promising Pipeline Molecules 97<br />
4.5.1 Adjuvant Immunotherapy 97<br />
4.5.2 Advanced Disease Immunotherapy 101<br />
4.5.3 Advanced Disease Targeted Therapy 103<br />
4.6 Heat Map <strong>and</strong> Competi<strong>to</strong>r Matrix for Pipeline Products 110<br />
5 <strong>Market</strong> Forecast <strong>to</strong> <strong>2020</strong> 117<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
5.1 Geographical <strong>Market</strong>s 117<br />
5.2 Global <strong>Market</strong> 118<br />
5.3 North America 121<br />
5.3.1 <strong>Treatment</strong> Usage Patterns 121<br />
5.3.2 Annual Cost of Therapy 123<br />
5.3.3 <strong>Market</strong> Size 124<br />
5.4 Top Five EU <strong>Market</strong>s 126<br />
5.4.1 <strong>Treatment</strong> Usage Patterns 126<br />
5.4.2 Annual Cost of Therapy 127<br />
5.4.3 <strong>Market</strong> Size 129<br />
5.5 Japan 130<br />
5.5.1 <strong>Treatment</strong> Usage Patterns 130<br />
5.5.2 Annual Cost of Therapy 131<br />
5.5.3 <strong>Market</strong> Size 132<br />
5.6 <strong>Drive</strong>r <strong>and</strong> Barriers for the <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong> 132<br />
5.6.1 <strong>Drive</strong>rs 132<br />
5.6.2 Barriers 134<br />
6 Strategic Consolidations 135<br />
6.1 Overview 135<br />
6.2 Co-development Deals 135<br />
6.2.1 GlaxoSmithKline Enters in<strong>to</strong> Co-development Agreement with Synta Pharma for<br />
elesclomol (STA-4783) – Deal Now Terminated 140<br />
6.2.2 Exelixis Enters in<strong>to</strong> Co-development Agreement with Genentech for cobimetinib 140<br />
6.2.3 Roche Enters in<strong>to</strong> Co-development Agreement with Bris<strong>to</strong>l-Myers Squibb for<br />
Zelboraf/Yervoy Combination Drug - No Longer Under Development for <strong>Melanoma</strong> 141<br />
6.3 Licensing Deals 141<br />
6.3.1 Chugai Pharma Enters in<strong>to</strong> Licensing Agreement with Roche for Zelboraf 146<br />
6.3.2 Colby Enters in<strong>to</strong> Licensing Agreement with MannKind for Cancer Immunotherapy<br />
Products – No Longer Under Development for <strong>Melanoma</strong> 146<br />
6.3.3 Molecular Insight Enters in<strong>to</strong> Licensing Agreement with Bayer Schering Pharma for<br />
Solazed – No Longer Under Development for <strong>Melanoma</strong> - No Longer Under Development for<br />
<strong>Melanoma</strong> 146<br />
7 Appendix 147<br />
7.1 All Pipeline Drugs by Phase of Development 149<br />
7.1.1 Discovery 149<br />
7.1.2 Preclinical 151<br />
7.1.3 IND/CTA-filed 157<br />
7.1.4 Phase I 157<br />
7.1.5 Phase II 160<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
7.1.6 Phase III 165<br />
7.1.7 Pre-registration 166<br />
7.2 <strong>Market</strong> Forecasts <strong>to</strong> <strong>2020</strong> 166<br />
7.2.1 Global 166<br />
7.2.2 US 166<br />
7.2.3 Canada 167<br />
7.2.4 UK 167<br />
7.2.5 France 168<br />
7.2.6 2.2.6 Germany 168<br />
7.2.7 Italy 169<br />
7.2.8 Spain 169<br />
7.2.9 Japan 170<br />
7.3 References 170<br />
7.3.1 References for Heat Maps 180<br />
7.4 Abbreviations 183<br />
7.5 <strong>Research</strong> Methodology 185<br />
7.5.1 Secondary <strong>Research</strong> 186<br />
7.5.2 <strong>Market</strong>ed Product Profiles 186<br />
7.5.3 Late-Stage Pipeline C<strong>and</strong>idates 186<br />
7.5.4 Comparative Efficacy <strong>and</strong> Safety Heat Map for <strong>Market</strong>ed <strong>and</strong> Pipeline Products 186<br />
7.5.5 Product Competitiveness Framework 187<br />
7.5.6 Pipeline Analysis 187<br />
7.5.7 Forecasting Model 188<br />
7.5.8 Deals Data Analysis 189<br />
7.6 Contact Us 189<br />
7.7 Disclaimer 189<br />
List Of Tables<br />
Table 1: Characteristics of Types of <strong>Melanoma</strong> 13<br />
Table 2: Staging of Cutaneous <strong>Melanoma</strong> 24<br />
Table 3: <strong>Melanoma</strong> Clinical Trial Endpoint Definitions 34<br />
Table 4: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, Groups of Molecular Targets, 2014<br />
77<br />
Table 5: Breakdown of ‘Other’ Molecular Targets 147<br />
Table 6: Breakdown of Molecular Target Combinations 148<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Table 7: <strong>Melanoma</strong> <strong>Therapeutics</strong>, Global, All Pipeline Products, Discovery Phase, 2014 149<br />
Table 8: <strong>Melanoma</strong> <strong>Therapeutics</strong>, Global, All Pipeline Products, Preclinical Phase, 2014 151<br />
Table 9: <strong>Melanoma</strong> <strong>Therapeutics</strong>, Global, All Pipeline Products, IND/CTA-filed Phase, 2014 157<br />
Table 10: <strong>Melanoma</strong> <strong>Therapeutics</strong>, Global, All Pipeline Products, Phase I, 2014 157<br />
Table 11: <strong>Melanoma</strong> <strong>Therapeutics</strong>, Global, All Pipeline Products, Phase II, 2014 160<br />
Table 12: <strong>Melanoma</strong> <strong>Therapeutics</strong>, Global, All Pipeline Products, Phase III, 2014 165<br />
Table 13: <strong>Melanoma</strong> <strong>Therapeutics</strong>, Global, All Pipeline Products, Pre-registration Phase, 2014<br />
166<br />
Table 14: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 166<br />
Table 15: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, US, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 166<br />
Table 16: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Canada, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 167<br />
Table 17: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, UK, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 167<br />
Table 18: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, France, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 168<br />
Table 19: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Germany, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 168<br />
Table 20: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Italy, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 169<br />
Table 21: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Spain, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 169<br />
Table 22: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Japan, <strong>Market</strong> Forecast, 2013–<strong>2020</strong> 170<br />
Table 23: List of Abbreviations 183<br />
List Of Figures<br />
Figure 1: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Adjuvant <strong>Market</strong>ed Products,<br />
2014 65<br />
Figure 2: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Advanced <strong>Market</strong>ed Products,<br />
2014 66<br />
Figure 3: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Advanced <strong>Market</strong>ed Products,<br />
2014 (continued) 67<br />
Figure 4: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, 2014 71<br />
Figure 5: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, Breakdown of Biologics <strong>and</strong><br />
Gene/Cell Therapies, 2014 73<br />
Figure 6: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, Repositioned Molecules by Original<br />
Indication, 2014 74<br />
Figure 7: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline by Molecular Target, 2014 76<br />
Figure 8: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, Breakdown of Protein Kinase<br />
Molecular Targets by Phase of Development, 2014 78<br />
Figure 9: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, Breakdown of Antigens/Antigen<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Lig<strong>and</strong>s Molecular Targets by Phase of Development, 2014 80<br />
Figure 10: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, Breakdown of Cy<strong>to</strong>kine/Cy<strong>to</strong>kine<br />
Recep<strong>to</strong>r Molecular Targets by Phase of Development, 2014 81<br />
Figure 11: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Clinical Trial Failure Rates by Phase of<br />
Development <strong>and</strong> Overall Clinical Trial Attrition Rate, 2006–2013 (%) 82<br />
Figure 12: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Clinical Trial Failure Rates (Phases I, II <strong>and</strong><br />
III) <strong>and</strong> Clinical Trial Attrition Rate by Molecule Type (%), 2006–2013 83<br />
Figure 13: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Clinical Trial Failure Rates (Phases I, II <strong>and</strong><br />
III) <strong>and</strong> Clinical Trial Attrition Rate by Molecular Target (%), 2006–2013 85<br />
Figure 14: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, Clinical Trial Duration by Molecule<br />
Type (months), 2006–2013 87<br />
Figure 15: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Clinical Trial Size by Molecule Type<br />
(participants), 2006–2013 89<br />
Figure 16: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Failure Rate, Average Trial Duration <strong>and</strong><br />
Average Trial Recruitment Size by Molecule Type, 2006–2013 91<br />
Figure 17: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Pipeline, Primary Clinical Trial Endpoints by<br />
Phase of Development (%), 2006–2013 92<br />
Figure 18: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Breakdown of Safety/drug Biochemistry <strong>and</strong><br />
Efficacy Clinical Trial Primary Endpoints by Phase of Development, 2006–2013 93<br />
Figure 19: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Secondary Clinical Trial Endpoints by Phase<br />
of Development (%), 2006–2013 94<br />
Figure 20: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Breakdown of Safety/drug biochemistry,<br />
Efficacy <strong>and</strong> ‘Other’ Clinical Trial Secondary Endpoints by Phase of Development, 2006–2013 96<br />
Figure 21: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global Sales Forecast for Seviprotimut-L ($m),<br />
2017–<strong>2020</strong> 99<br />
Figure 22: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Sales Forecast for Yervoy (Adjuvant Setting)<br />
($m), 2016–<strong>2020</strong> 101<br />
Figure 23: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global Sales Forecast for Talimogene<br />
Laherparepvec (T-Vec) ($m), 2015–<strong>2020</strong> 103<br />
Figure 24: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Sales Forecast for Selumetinib ($m), 2016–<br />
<strong>2020</strong> 106<br />
Figure 25: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global Sales Forecast for Binimetinib ($m), 2016–<br />
<strong>2020</strong> 108<br />
Figure 26: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Sales Forecast for Cobimetinib ($m), 2015–<br />
<strong>2020</strong> 110<br />
Figure 27: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Adjuvant Pipeline Products,<br />
2014 111<br />
Figure 28: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Advanced Pipeline Products,<br />
2014 112<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Figure 29: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Advanced Pipeline Products,<br />
2014 (continued) 113<br />
Figure 30: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Competi<strong>to</strong>r Matrix for Advanced Products,<br />
2014 114<br />
Figure 31: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, <strong>Treatment</strong> Patterns (‘000) <strong>and</strong> <strong>Market</strong> Size<br />
($bn), 2013–<strong>2020</strong> 118<br />
Figure 32: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, North America, <strong>Treatment</strong> Patterns, 2013–<strong>2020</strong> 122<br />
Figure 33: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, North America, Annual Cost of Therapy ($), 2013–<br />
<strong>2020</strong> 123<br />
Figure 34: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, North America, <strong>Market</strong> Size, 2013–<strong>2020</strong> 125<br />
Figure 35: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Five EU Countries, <strong>Treatment</strong> Patterns (‘000), 2013–<br />
<strong>2020</strong> 126<br />
Figure 36: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Top Five EU Countries, Annual Cost of Therapy ($),<br />
2013–<strong>2020</strong> 128<br />
Figure 37: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Top Five EU Countries, <strong>Market</strong> Size ($m), 2013–<br />
<strong>2020</strong> 129<br />
Figure 38: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Japan, <strong>Treatment</strong> Usage Patterns (‘000), 2013–<strong>2020</strong><br />
130<br />
Figure 39: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Japan, Annual Cost of Therapy ($), 2013–<strong>2020</strong> 131<br />
Figure 40: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Japan, <strong>Market</strong> Size ($m), 2013–<strong>2020</strong> 132<br />
Figure 41: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Co-development Deals by Region, 2006–<br />
2014 135<br />
Figure 42: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Co-development Deals by Deal Value, 2006–<br />
2014 136<br />
Figure 43: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Co-development Deals by Year, 2006–2014<br />
137<br />
Figure 44: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Co-development Deals by Phase of<br />
Development, Deal Value <strong>and</strong> Upfront Payment ($m), 2006–2014 138<br />
Figure 45: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Co-development Deals by Phase of Development,<br />
Molecule Type <strong>and</strong> Aggregate Deal Value ($m), 2006–2014 139<br />
Figure 46: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Licensing Deals by Region, 2006–2014 141<br />
Figure 47: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Licensing Deals by Deal Value, 2006–2014<br />
142<br />
Figure 48: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Licensing Deals by Year, 2006–2014 143<br />
Figure 49: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Licensing Deals by Phase of Development,<br />
Deal Value <strong>and</strong> Upfront Payment ($m), 2006–2014 144<br />
Figure 50: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Licensing Deals by Phase of Development, Molecule<br />
Type <strong>and</strong> Aggregate Deal Value ($m), 2006–2014 145<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Report Price:<br />
Licence Type<br />
Price<br />
PDF $ 4995<br />
Site Licence $ 9990<br />
Enterprise Wide Licence $ 14985<br />
Related Reports:<br />
Complicated Intra-Abdominal Infections Global Clinical Trials Review, H2, 2014<br />
Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014<br />
H1N1 Infection Global Clinical Trials Review, H2, 2014<br />
Post-Operative Pain - Pipeline Review, H2 2014<br />
Retinitis Pigmen<strong>to</strong>sa (Retinitis) - Pipeline Review, H2 2014<br />
Recurrent Glioblas<strong>to</strong>ma Multiforme (GBM) - Pipeline Review, H2 2014<br />
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2014<br />
Critical Limb Ischemia - Pipeline Review, H2 2014<br />
Thyroid Cancer - Pipeline Review, H2 2014<br />
Fragile X Syndrome - Pipeline Review, H2 2014<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
You can order this report by calling on +91 - 998 7295 242 or mail us<br />
your contact details at contact@jsbmarketresearch.com<br />
About <strong>JSB</strong> <strong>Market</strong> <strong>Research</strong>:-<br />
<strong>JSB</strong> market research is a leading player in the market of research report distribution. It is ones<strong>to</strong>p-shop<br />
for all information related <strong>to</strong> market research for any sec<strong>to</strong>r of the industry. Along<br />
with providing in-depth analysis though reports, <strong>JSB</strong> market research also provides regular<br />
updates of the market though newsletters. Our reports are a well-researched work of market<br />
researchers with an extensive knowledge <strong>and</strong> a good level of market experience.<br />
To know more on <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong> <strong>to</strong> <strong>2020</strong> - <strong>Rising</strong> <strong>Prevalence</strong><br />
<strong>and</strong> <strong>Evolving</strong> <strong>Treatment</strong> <strong>Algorithms</strong> <strong>to</strong> <strong>Drive</strong> <strong>Market</strong> <strong>Growth</strong><br />
http://www.jsbmarketresearch.com/healthcare-medical/r-melanomatherapeutics-market-<strong>to</strong>-<strong>2020</strong>-rising-prevalence-<strong>and</strong>-evolving-treatmentalgorithms-<strong>to</strong>-drive-market-growth-138194<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/